Dongkoo Bio&Pharma Co Ltd
006620
Company Profile
Business description
Dongkoo Bio&Pharma Co Ltd is engaged in the research, development, manufacture, and sale of pharmaceuticals products. The company provides products for digestants, other analgesics and antipyretics, nonsteroidal anti-inflammatory drugs, oral hypoglycemic agents, antiplatelet agents, antihistamines and anti-allergic, and decongestants and nasal sprays. It offers its products in multiple forms such as capsules, tablet, powder, granule, and liquid. The company exports its products to various countries including Vietnam, New Zealand, Thailand, Hong Kong and Singapore.
Contact
B-14F, M State Building, 114, Beobwonro, Songpagu
Seoul05836
KORT: +82 226845421
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
418
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,688.60 | 34.35 | 0.45% |
| DAX 40 | 23,569.17 | 81.84 | 0.35% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,136.80 | 20.11 | 0.22% |
| HKSE | 25,337.36 | 159.19 | -0.62% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |